Trump’s new drug pricing proposals have already sparked a war of words with the drug industry

WASHINGTON — The Trump administration’s new plan to pay for certain drugs in Medicare based on international prices quickly set off a war with the drug industry after it was unveiled Thursday — and both sides are charging ahead with aggressive statements that the other is ignoring patients.

The trade group for drug makers, PhRMA, called the proposal “price controls” and said it was “disappointed the administration put the needs of patients aside with these proposals.”